STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 102 filers reported holding STOKE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $226,779 | +4.8% | 57,558 | +182.9% | 0.00% | – |
| Q2 2023 | $216,289 | +1.7% | 20,347 | -20.3% | 0.00% | – |
| Q1 2023 | $212,681 | -7.9% | 25,532 | +2.1% | 0.00% | – |
| Q4 2022 | $230,861 | +207.8% | 25,012 | +327.5% | 0.00% | – |
| Q3 2022 | $75,000 | -65.1% | 5,851 | -64.2% | 0.00% | – |
| Q2 2022 | $215,000 | +18.1% | 16,322 | +89.1% | 0.00% | – |
| Q1 2022 | $182,000 | -85.9% | 8,632 | -83.9% | 0.00% | – |
| Q4 2021 | $1,289,000 | +502.3% | 53,742 | +540.0% | 0.00% | – |
| Q3 2021 | $214,000 | -48.4% | 8,397 | -31.9% | 0.00% | – |
| Q2 2021 | $415,000 | -16.5% | 12,323 | -3.8% | 0.00% | – |
| Q1 2021 | $497,000 | +126.9% | 12,811 | +263.0% | 0.00% | – |
| Q4 2020 | $219,000 | +63.4% | 3,529 | -11.4% | 0.00% | – |
| Q3 2020 | $134,000 | -38.5% | 3,983 | -56.5% | 0.00% | – |
| Q2 2020 | $218,000 | +62.7% | 9,156 | +56.5% | 0.00% | – |
| Q1 2020 | $134,000 | +31.4% | 5,849 | +61.9% | 0.00% | – |
| Q4 2019 | $102,000 | +29.1% | 3,613 | -2.7% | 0.00% | – |
| Q3 2019 | $79,000 | – | 3,714 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |